文献速递临床试验与 GCP

碳酸钙补充预防高危孕妇子痫前期:一项随机临床试验方案

Calcium carbonate supplementation for the prevention of preeclampsia in high-risk pregnant women: a randomized clinical trial protocol.
PubMed 文献 · Trials · 2024-10-03

该方案计划于2024年5月至2026年3月在巴西一家门诊开展三盲随机临床试验,纳入子痫前期高危且膳食钙摄入低的孕妇,随机分为工业碳酸钙胶囊联合100 mg阿司匹林组、源自牡蛎(Crassostrea sp.)的碳酸钙联合100 mg阿司匹林组及安慰剂联合100 mg阿司匹林对照组,主要结局为孕期子痫前期诊断,旨在评估碳酸钙预防子痫前期的 efficacy 并比较两种钙源。

要点

  • 世界卫生组织推荐孕期使用低剂量阿司匹林(100 mg)和1.5至2 g碳酸钙预防子痫前期。
  • 该三盲随机试验在巴西门诊开展,纳入子痫前期高危且膳食钙摄入低的孕妇。
  • 三组均联合100 mg阿司匹林,比较工业碳酸钙、牡蛎源碳酸钙与安慰剂的预防效果。

核心结论

  • 该试验旨在生成碳酸钙预防子痫前期的疗效证据,并重点比较工业碳酸钙与源自牡蛎(Crassostrea sp.)的碳酸钙这一更可持续的替代来源。

研究设计与样本

  • 三盲随机临床试验方案,计划于2024年5月至2026年3月在巴西一家门诊开展。
  • 纳入子痫前期高危且膳食钙摄入低的孕妇,随机分为三组:工业碳酸钙胶囊联合100 mg阿司匹林组、源自牡蛎(Crassostrea sp.)的碳酸钙联合100 mg阿司匹林组、安慰剂联合100 mg阿司匹林对照组。
  • 主要结局为孕期子痫前期诊断,次要结局评估母婴健康指标。
  • 研究经塞尔希培联邦大学研究伦理委员会批准,并在巴西临床试验注册中心(ReBEC)注册,注册号为RBR-7hqhj3y,注册日期为2023年11月16日。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preeclampsia (PE) is a significant cause of maternal mortality worldwide, affecting 2% to 8% of pregnancies. The World Health Organization recommends the use of low-dose acetylsalicylic acid (100 mg of aspirin) and 1.5 to 2 g of calcium carbonate during pregnancy to prevent PE. However, robust evidence supporting the efficacy of calcium supplementation is still needed. This study aims to assess the efficacy of calcium carbonate in preventing preeclampsia in high-risk pregnant women. METHODS: A triple-blind, randomized clinical trial will be conducted at an outpatient clinic in Brazil between May 2024 and March 2026. Pregnant women at high risk of developing preeclampsia and with low dietary calcium intake will be randomly assigned to one of three groups: one group will receive calcium carbonate capsules (commercially available in Brazil) along with 100 mg of aspirin; the second group will receive calcium carbonate derived from Crassostrea sp. along with 100 mg of aspirin; and the control group will receive a placebo alongside 100 mg of aspirin. The primary outcome is the diagnosis of preeclampsia during pregnancy, while secondary outcomes evaluate maternal and fetal health indicators. DISCUSSION: This trial seeks to generate evidence on the efficacy of calcium carbonate in preeclampsia prevention, with a focus on comparing industrial calcium carbonate with calcium carbonate sourced from Crassostrea sp., a more sustainable alternative. TRIAL REGISTRATION: The study was approved by the Research Ethics Committee of the Federal University of Sergipe and registered in the Brazilian Registry of Clinical Trials (ReBEC), under the ID RBR-7hqhj3y. Registered on November 16, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Oliveira CRV, Resende CL, Neves SJF, et al. Calcium carbonate supplementation for the prevention of preeclampsia in high-risk pregnant women: a randomized clinical trial protocol. Trials. 2024. PMID: 39363375. doi:10.1186/s13063-024-08489-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。